Affiliation:
1. Departament de Medicina i Cirurgia Animals, Fundació Hospital Clínic Veterinari, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
Abstract
The treatment of canine leishmaniosis commonly involves meglumine antimoniate with allopurinol or miltefosine with allopurinol. This study aims to compare the clinical and clinicopathological efficacy at 28–30 days of conventional dosing regimens for both treatments using the critically appraised topic methodology. A comprehensive search across three databases (PubMed, CAB Abstracts, and Web of Science) from March 2004 to September 2023 yielded 16 relevant articles, encompassing 325 ogs treated with meglumine antimoniate and allopurinol, and 273 dogs treated with miltefosine and allopurinol. The findings indicated a significantly higher rate of complete clinical cure in the group treated with meglumine antimoniate and allopurinol. Most dogs in both groups exhibited improvement in clinicopathological alterations after one month of treatment. No significant difference was observed in the number of dogs that showed a negative Leishmania qPCR between the two groups, one month post-treatment. However, quantitative serology results were not commonly reported in the available data and therefore this aspect could not be compared.
Reference36 articles.
1. Directions for the diagnosis, clini-cal staging, treatment and prevention of canine leishmaniosis;Koutinas;Vet. Parasitol.,2009
2. LeishVet guidelines for the practi-cal management of canine leishmaniosis;Koutinas;Parasites Vectors,2011
3. Novel Areas for Prevention and Control of Canine Leishmaniosis;Petersen;Trends Parasitol.,2017
4. Meglumine antimonate directly increases phagocytosis, superoxide anion and TNF-α production, but only via TNF-α it indirectly increases nitric oxide production by phagocytes of healthy individuals, in vitro;Int. Immunopharmacol.,2008
5. Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis;Dorlo;J. Antimicrob. Chemother.,2012